Related Experiment Video
Updated: Jun 5, 2026
08:40
Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Towards molecular imaging of multiple sclerosis
David R J Owen1, Paola Piccini, Paul M Matthews
1Division of Experimental Medicine, Imperial College, Hammersmith Hospital, London, UK.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|January 8, 2011
Summary
Positron emission tomography (PET) offers molecularly specific imaging to complement MRI for multiple sclerosis (MS) research. This sensitive technique uses microdoses of radioligands, enabling rapid development for insights into MS pathology and treatment selection.
Area of Science:
- Neuroimaging
- Molecular Imaging
- Radiochemistry
Background:
- Magnetic resonance imaging (MRI) is crucial for multiple sclerosis (MS) research and clinical management.
- MRI signal changes in MS are often indirect and non-specific indicators of neuropathology.
- There is a need for more specific molecular markers to understand MS disease processes.
Purpose of the Study:
- To highlight the potential of Positron Emission Tomography (PET) in complementing MRI for MS.
- To discuss how PET can provide quantitative, molecularly specific insights into MS.
- To explore the future role of molecular imaging in MS patient stratification and treatment optimization.
Main Methods:
- Utilizing existing and novel PET radiotracers to image specific cellular and metabolic processes.
- Employing PET's high sensitivity, enabling imaging with picomolar concentrations of radioligands.
- Administering microdoses (<10 µg) of radioligands, reducing the need for extensive toxicology studies.
Main Results:
- PET offers quantitative measures of molecularly specific markers relevant to MS.
- Available PET radiotracers can provide insights into innate immune response, neuronal function, neurodegeneration, and remyelination.
- The microdose requirement for PET facilitates rapid implementation of new radioligands.
Conclusions:
- PET imaging holds significant promise for advancing the understanding of multiple sclerosis pathophysiology.
- Molecular imaging with PET can offer a more specific and quantitative assessment of MS compared to MRI alone.
- PET has the potential to aid in clinical decision-making by enabling patient stratification for personalized treatment strategies.
